1. Home
  2. MARA vs RYTM Comparison

MARA vs RYTM Comparison

Compare MARA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marathon Digital Holdings Inc.

MARA

Marathon Digital Holdings Inc.

HOLD

Current Price

$14.82

Market Cap

5.4B

Sector

Technology

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$107.76

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MARA
RYTM
Founded
2010
2008
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.8B
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
MARA
RYTM
Price
$14.82
$107.76
Analyst Decision
Buy
Strong Buy
Analyst Count
12
14
Target Price
$17.85
$131.14
AVG Volume (30 Days)
39.0M
814.7K
Earning Date
05-05-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.34
EPS
N/A
N/A
Revenue
$907,093,000.00
N/A
Revenue This Year
N/A
$55.34
Revenue Next Year
$13.31
$86.06
P/E Ratio
N/A
N/A
Revenue Growth
38.20
N/A
52 Week Low
$6.66
$62.29
52 Week High
$23.45
$122.20

Technical Indicators

Market Signals
Indicator
MARA
RYTM
Relative Strength Index (RSI) 57.97 75.44
Support Level $11.68 $98.30
Resistance Level $15.32 $113.03
Average True Range (ATR) 1.30 5.00
MACD -0.02 2.22
Stochastic Oscillator 59.39 86.42

Price Performance

Historical Comparison
MARA
RYTM

About MARA Marathon Digital Holdings Inc.

MARA Holdings Inc leverages digital asset computing to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for Bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: